Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PROK 
ProKidney Corp. (PROK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PROK (1-star) is a SELL. SELL since 2 days. Simulated Profits (-2.78%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.4
1 Year Target Price $5.4
| 4 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.93% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 829.70M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 7 | Beta 1.8 | 52 Weeks Range 0.46 - 5.95 | Updated Date 11/7/2025 |
52 Weeks Range 0.46 - 5.95 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17967.87% |
Management Effectiveness
Return on Assets (TTM) -25.3% | Return on Equity (TTM) -40.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84972013 | Price to Sales(TTM) 1574.38 |
Enterprise Value 84972013 | Price to Sales(TTM) 1574.38 | ||
Enterprise Value to Revenue 161.24 | Enterprise Value to EBITDA 2.13 | Shares Outstanding 135977945 | Shares Floating 87070827 |
Shares Outstanding 135977945 | Shares Floating 87070827 | ||
Percent Insiders 26.62 | Percent Institutions 30.1 |
Upturn AI SWOT
ProKidney Corp.
Company Overview
History and Background
ProKidney Corp. is a biotechnology company focused on developing cell therapies for kidney disease. Founded in 2015, it aims to prevent or delay the need for dialysis in patients with chronic kidney disease (CKD). The company went public via SPAC merger.
Core Business Areas
- Cell Therapy Development: Developing and commercializing REACTu00ae, a proprietary autologous cell therapy for CKD.
Leadership and Structure
Clara Kim, M.D., Ph.D., is the Chief Medical Officer and President. The company operates with a functional organizational structure centered on research, clinical development, and manufacturing.
Top Products and Market Share
Key Offerings
- REACTu00ae: REACTu00ae is an autologous cell therapy in Phase 3 clinical trials designed to treat chronic kidney disease (CKD). It aims to use a patient's own kidney cells to promote kidney function and delay or prevent dialysis. Market share data is currently not applicable as the product is not yet commercialized. Competitors in the CKD treatment space include pharmaceutical companies developing drugs to manage CKD symptoms and slow progression, such as AstraZeneca and Bayer, as well as dialysis providers like DaVita and Fresenius.
Market Dynamics
Industry Overview
The kidney disease treatment market is large and growing, driven by the increasing prevalence of diabetes and hypertension, major causes of CKD. There is a significant unmet need for therapies that can prevent or delay the need for dialysis.
Positioning
ProKidney is positioning itself as a pioneer in cell therapy for kidney disease, offering a potentially disease-modifying treatment option compared to existing symptom management strategies.
Total Addressable Market (TAM)
The global CKD market is estimated to be over $80 billion. ProKidney is targeting a segment of this market with REACTu00ae, focusing on patients with earlier stages of CKD to delay dialysis. The company's position within the TAM is as an innovator attempting to reshape the treatment paradigm.
Upturn SWOT Analysis
Strengths
- Novel cell therapy technology
- Focus on a large and underserved market
- Experienced leadership team
- Proprietary technology
Weaknesses
- Product not yet approved
- High development and manufacturing costs
- Reliance on clinical trial success
- Limited commercial history
Opportunities
- Partnerships with pharmaceutical companies or dialysis providers
- Expansion to other kidney disease indications
- Positive clinical trial results leading to FDA approval
- Growing prevalence of CKD
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established dialysis providers and pharmaceutical companies
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- AZN
- BAYRY
- DVA
- FMS
Competitive Landscape
ProKidney differentiates itself through its cell therapy approach, targeting a disease-modifying outcome rather than symptom management like other competitors. However, it faces challenges in competing with established companies with existing market share and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the clinical development stage.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval of REACTu00ae. Analyst estimates vary based on the probability of success and market penetration assumptions.
Recent Initiatives: Advancing Phase 3 clinical trials of REACTu00ae, securing partnerships for manufacturing and distribution, and presenting clinical data at scientific conferences.
Summary
ProKidney is a high-risk, high-reward biotechnology company focusing on cell therapy for chronic kidney disease. Its success hinges on the positive outcomes of its ongoing Phase 3 clinical trials of REACTu00ae. It faces competition from established players but offers a potentially disruptive technology. The company's financial stability is reliant on continued funding and successful commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- ProKidney Corp. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProKidney Corp.
Exchange NASDAQ | Headquaters Winston-Salem, NC, United States | ||
IPO Launch date 2022-07-12 | CEO & Director Dr. Bruce Culleton M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 204 | Website https://prokidney.com |
Full time employees 204 | Website https://prokidney.com | ||
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.